Tagged with Pierre Fabre

France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…

France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.   A reform-minded and business-oriented administration under President Emmanuel Macron…

France Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million since 2014. It is, however, the company’s unique positioning right at the confluence between the worlds of medicines and cosmetics…

France Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging markets strategy, while reaffirming Pierre Fabre’s commitment to France’s healthcare innovation ecosystem. As illustrated by the group’s new motto ‘Taking…

Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future.   David Meek, Ipsen David…

China Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic one, since his appointment in 2016. He also discusses the value of Pierre Fabre’s oncology portfolio for the region and…

Hong Kong Frederic Charles, CEO of Pierre Fabre Hong Kong and Macau, outlines brand perceptions of Pierre Fabre’s dermatological products in Hong Kong, e-commerce, and other emerging skincare trends in Asia.   With the opening of Pierre Fabre Hong Kong affiliate in 2016, what were the main achievements so far? The affiliate…

Algeria Nawel Baba Hamed, general director of Pierre Fabre Algeria, outlines the French company’s product portfolio in Algeria, its dermatological expertise, and the growing significance of its oncology segment.   Could you introduce our readers to Pierre Fabre and its footprint in Algeria? Pierre Fabre is the second-largest dermo-cosmetic laboratory in…

Turkey Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the dynamic Turkish market. In this interview, the experienced General Manager discusses the advantages of diversifying strategies, Pierre Fabre’s comparative advantage…

UK Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the affiliate the best performing in the coming years. She also details the strong heritage of Oncology and the affiliate’s exciting…

Poland Philippe Coudiere, general manager of Pierre Fabre Dermo-cosmetics Poland, highlights the key partnerships the company has nurtured with pharmacists and dermatologists and the importance of clinical data for their products. Furthermore, he explains the need to develop a strong connection with end consumers and the dynamics of the Polish dermo-cosmetic…

Brazil Alex Carvalho, general manager Pierre Fabre Brazil, provides insights into the rapidly ascending trajectory of the company in Brazil, its utmost commitment to oncology in the country, and Pierre Fabre’s eagerness to further investing in this strategic market. He also calls for a greater collaboration between all stakeholders to tackle…